Health Condition 1: C509- Malignant neoplasm of breast of unspecified site Health Condition 2: C159- Malignant neoplasm of esophagus, unspecified Health Condition 3: C169- Malignant neoplasm of stomach, unspecified Health Condition 4: C569- Malignant neoplasm of unspecifiedovary Health Condition 5: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
Conditions
Interventions
None listed
Sponsors
Strand Life Sciences Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with confirmed malignant neoplasm who are eligible for chemotherapy or radiation therapy. 2. Relapsed or metastatic cases who are undergoing chemo or radiation therapy, as identified by the site Principal Investigator or co-Investigators through routine clinical care processes. 3. Age- 18 years and above. 4. Both men and women of all races and ethnic groups are eligible for this study. 5. Ability to understand and the willingness to sign a written Informed Consent Form.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women. 2. Patients who have an uncontrolled infection. 3. Patients who are receiving any oncology investigational agent(s), enrolled in other studies. 4. Patients who are coagulopathic and are taking blood thinning products.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This study will enable the identification of biomarkers to evaluate response patterns of patients undergoing chemotherapy or radiation therapy and aid in the identification of markers for precision guided cancer treatment for better outcomes.Timepoint: Outcome will be assessed at the end of the therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| To delineate the molecular mechanism underlying drug resistance to achieve better clinical outcomes.Timepoint: Outcome will be assessed at the end of the therapy | — |
Countries
India
Contacts
Public ContactDr Vamsi Veeramachaneni
Strand Life Sciences Private Limited
Outcome results
None listed